Ironwood Pharmaceuticals Projects $475M Revenue for Fiscal 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy IRWD?
Source: NASDAQ.COM
- Fiscal 2026 Outlook: Ironwood projects total revenue between $450 million and $475 million for fiscal 2026, with Adjusted EBITDA exceeding $300 million, indicating strong growth potential in the biotechnology sector.
- Fiscal 2025 Confirmation: The company maintains its revenue expectations for fiscal 2025 in the range of $290 million to $310 million, with Adjusted EBITDA anticipated to surpass $135 million, reflecting business stability and ongoing profitability.
- Cash Flow Position: As of Q4 2025, Ironwood reported over $200 million in cash and cash equivalents, ensuring financial flexibility for future R&D and operations.
- Clinical Trial Progress: Ironwood has aligned with the FDA to initiate a confirmatory Phase 3 trial for apraglutide targeting short bowel syndrome in the first half of 2026, which is expected to enhance the company's market position in this therapeutic area.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRWD
Wall Street analysts forecast IRWD stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.610
Low
5.00
Averages
6.23
High
8.00
Current: 4.610
Low
5.00
Averages
6.23
High
8.00
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
- Investment Resumption: President Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry following the ousting of Maduro, aiming to restore the country's dilapidated oil infrastructure and stimulate economic recovery.
- Oil Price Fluctuations: Following geopolitical developments, WTI February futures traded 0.05% lower at $57.29 per barrel early Monday, indicating market caution regarding future oil price trends.
- Market Expectations: The CME Group's FedWatch tool indicates an 82.3% likelihood that the Federal Reserve will keep interest rates unchanged in January, which could influence investor confidence in the stock market.
- Stock Market Performance: In premarket trading on Monday, the SPDR S&P 500 ETF (SPY) rose 0.22% to $684.68, while the Invesco QQQ Trust ETF (QQQ) increased by 0.51% to $616.26, reflecting optimistic sentiment regarding economic recovery.
See More
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
- Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
- Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
- Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
- Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
ChowChow Cloud Reports 29% Revenue Growth in H1 2025
- Market Volatility: U.S. stocks traded mixed, with the Dow Jones gaining 0.27% to 48,195.28 points while the NASDAQ fell 0.14% to 23,209.54 points, reflecting uncertainty in the market and divergent investor sentiment.
- Manufacturing PMI Decline: The S&P Global Manufacturing PMI fell from 52.2 to 51.8 in December, indicating a slowdown in manufacturing activity that could impact future economic growth expectations, prompting businesses to adjust strategies to navigate potential market challenges.
- ChowChow Cloud Stock Surge: ChowChow Cloud International Holdings Limited saw its shares rise 29% to $0.78 after reporting year-over-year revenue and net income growth for H1 2025, showcasing the company's strong performance and growth potential in the market.
- Ironwood Pharmaceuticals Guidance Boost: Ironwood Pharmaceuticals, Inc. shares surged 43% to $4.80 following the issuance of FY26 guidance, reflecting the company's confidence in future performance and potentially attracting more investor interest.
See More
Ironwood Pharmaceuticals Shares Surge Following Drug Price Reduction Enhancing Outlook
- Stock Performance: Ironwood Pharmaceuticals' shares surged over 30% in early trading of the new year.
- Sales Outlook: The increase in stock price was driven by a significantly improved sales forecast for 2026.
See More
Ironwood Pharmaceuticals Provides 2026 Guidance, LINZESS Sales Expected to Reach $1.125B to $1.175B
- Sales Forecast Increase: Ironwood anticipates LINZESS sales for fiscal year 2025 to range between $860 million and $890 million, representing a significant increase from $351.4 million in fiscal year 2024, indicating strong market demand and growth potential for the product.
- Total Revenue Outlook: The company expects total revenue for fiscal year 2025 to be between $290 million and $310 million, reflecting the ongoing profitability from its brand collaboration with AbbVie, which will continue to drive financial performance.
- Long-term Market Potential: Ironwood is exploring additional indications for LINZESS, including pediatric use for functional constipation in children aged 6 to 17 years, which will further broaden its market coverage and enhance future revenue streams.
- New Drug Development Progress: Apraglutide is advancing toward a confirmatory Phase 3 trial, which, if successful, could provide a key treatment option for patients with short bowel syndrome, with plans to initiate the trial in the first half of 2026, potentially creating a new revenue stream for the company.
See More
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
- Investment Resumption: President Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry following the ousting of Maduro, aiming to restore the country's dilapidated oil infrastructure and stimulate economic recovery.
- Oil Price Fluctuations: Following geopolitical developments, WTI February futures traded 0.05% lower at $57.29 per barrel early Monday, indicating market caution regarding future oil price trends.
- Market Expectations: The CME Group's FedWatch tool indicates an 82.3% likelihood that the Federal Reserve will keep interest rates unchanged in January, which could influence investor confidence in the stock market.
- Stock Market Performance: In premarket trading on Monday, the SPDR S&P 500 ETF (SPY) rose 0.22% to $684.68, while the Invesco QQQ Trust ETF (QQQ) increased by 0.51% to $616.26, reflecting optimistic sentiment regarding economic recovery.
See More
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
- Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
- Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
- Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
- Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
ChowChow Cloud Reports 29% Revenue Growth in H1 2025
- Market Volatility: U.S. stocks traded mixed, with the Dow Jones gaining 0.27% to 48,195.28 points while the NASDAQ fell 0.14% to 23,209.54 points, reflecting uncertainty in the market and divergent investor sentiment.
- Manufacturing PMI Decline: The S&P Global Manufacturing PMI fell from 52.2 to 51.8 in December, indicating a slowdown in manufacturing activity that could impact future economic growth expectations, prompting businesses to adjust strategies to navigate potential market challenges.
- ChowChow Cloud Stock Surge: ChowChow Cloud International Holdings Limited saw its shares rise 29% to $0.78 after reporting year-over-year revenue and net income growth for H1 2025, showcasing the company's strong performance and growth potential in the market.
- Ironwood Pharmaceuticals Guidance Boost: Ironwood Pharmaceuticals, Inc. shares surged 43% to $4.80 following the issuance of FY26 guidance, reflecting the company's confidence in future performance and potentially attracting more investor interest.
See More
Ironwood Pharmaceuticals Shares Surge Following Drug Price Reduction Enhancing Outlook
- Stock Performance: Ironwood Pharmaceuticals' shares surged over 30% in early trading of the new year.
- Sales Outlook: The increase in stock price was driven by a significantly improved sales forecast for 2026.
See More
Ironwood Pharmaceuticals Provides 2026 Guidance, LINZESS Sales Expected to Reach $1.125B to $1.175B
- Sales Forecast Increase: Ironwood anticipates LINZESS sales for fiscal year 2025 to range between $860 million and $890 million, representing a significant increase from $351.4 million in fiscal year 2024, indicating strong market demand and growth potential for the product.
- Total Revenue Outlook: The company expects total revenue for fiscal year 2025 to be between $290 million and $310 million, reflecting the ongoing profitability from its brand collaboration with AbbVie, which will continue to drive financial performance.
- Long-term Market Potential: Ironwood is exploring additional indications for LINZESS, including pediatric use for functional constipation in children aged 6 to 17 years, which will further broaden its market coverage and enhance future revenue streams.
- New Drug Development Progress: Apraglutide is advancing toward a confirmatory Phase 3 trial, which, if successful, could provide a key treatment option for patients with short bowel syndrome, with plans to initiate the trial in the first half of 2026, potentially creating a new revenue stream for the company.
See More
